Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience

INTRODUCTION: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Andrew, Huang, Ying, Kittai, Adam, Maakaron, Joseph E, Saygin, Caner, Brammer, Jonathan, Penza, Sam, Saad, Ayman, Jaglowski, Samantha M, William, Basem M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643129/
https://www.ncbi.nlm.nih.gov/pubmed/34876852
http://dx.doi.org/10.2147/CMAR.S321202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643129/
https://www.ncbi.nlm.nih.gov/pubmed/34876852
http://dx.doi.org/10.2147/CMAR.S321202

Ejemplares similares